DDRNA-based cancer therapy targeted telomeres

Informacje na temat projektu

DDRNA

Identyfikator umowy o grant: 664713

DOI

10.3030/664713

Projekt został zamknięty

Data podpisania przez KE 18 Maja 2015

Data rozpoczęcia 1 Czerwca 2015

Data zakończenia 30 Listopada 2016

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

€ 149 425,00

Wkład UE

€ 149 425,00

Koordynowany przez

IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS
Italy

Periodic Reporting for period 1 - DDRNA (DDRNA-based cancer therapy targeted telomeres)

Okres sprawozdawczy: 2015-06-01 do 2016-11-30

Podsumowanie kontekstu i ogólnych celów projektu

There is a clear unmet medical need for a subset of cancer patient population, 10-20% of all tumors, which rely on an alternative lengthening of telomeres (ALT) mechanisms to allow their growth. ALT positive tumors are generally more aggressive and resistant to radiotherapy and chemotherapy.
Thanks to the support of the ERC, we could extend the study of the impact of our anticancer approach to different human cancer cell lines. By doing so, we could confirm its efficacy and, most importantly, characterize better its specificity.
We also performed several experiments to establish a tentative mechanism of action, investigating the impact of our treatment at both the molecular and cellular level. Finally we tested its efficacy in in vivo cancer models, providing a strong preclinical evidence for a potential therapeutic application.
Importantly we have conducted the experimental activities always in tight conjunction with the exploitation of the results for maximizing the testing and commercial efforts.
The conclusions of these studies make us confident on the potential of our approach.